Tenaya Therapeutics And Alnylam Pharmaceuticals Partner To Discover Genetic Targets For Heart Disease Treatments

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing therapies that target the root causes of heart disease, announced that it has entered into a research collaboration agreement with Alnylam Pharmaceuticals. Alnylam is widely recognized as a leader in RNA interference (RNAi) therapeutics. The collaboration aims to identify new human genetic targets that could lead to the development of disease-modifying treatments for cardiovascular diseases.

Through this partnership, the two companies plan to combine their scientific expertise to advance research in cardiovascular medicine. Tenaya Therapeutics will focus on identifying and validating genetic targets that may play a critical role in heart disease, while Alnylam will use its expertise in RNA interference technology to potentially develop therapies based on those discoveries.

Faraz Ali, Chief Executive Officer of Tenaya Therapeutics, explained that the collaboration reflects the company’s continued focus on strong scientific research and innovation. He noted that Tenaya has built proprietary capabilities that have supported the discovery and development of its existing pipeline of candidates targeting cardiovascular conditions. By combining Tenaya’s approach to identifying and validating genetic targets with Alnylam’s leadership in RNAi therapeutics, the collaboration creates an opportunity to advance new candidates that could ultimately lead to transformative medicines for people living with heart disease.

Under the terms of the agreement, Tenaya Therapeutics will be responsible for validating up to 15 gene targets during the collaboration. The validation work will take place over a two-year period. As part of the agreement, Tenaya will receive an upfront payment of up to $10 million and will also be reimbursed for certain costs related to the research activities carried out during the validation phase. Once gene targets are identified and validated, Alnylam Pharmaceuticals will take responsibility for the further development and commercialization of therapies associated with those targets. 

This includes advancing potential treatments through clinical development and bringing them to market if successful. The agreement also includes the potential for additional financial milestones. If the research leads to approved therapeutics for cardiovascular diseases, Tenaya may be eligible to receive up to $1.13 billion in development and commercial milestone payments from Alnylam. These payments would be tied to the progress and eventual success of therapies developed from the validated gene targets.

The collaboration highlights the growing importance of genetic research in the development of new treatments for cardiovascular disease, which remains one of the leading causes of death globally. By identifying genetic drivers of heart disease and developing therapies designed to address those underlying mechanisms, companies like Tenaya and Alnylam aim to move beyond symptom management toward treatments that could significantly alter the course of disease. Through this partnership, both companies hope to accelerate the discovery of innovative therapeutic approaches and ultimately improve outcomes for patients affected by cardiovascular conditions.